Moreover, preclinical investigations showed that a subset of T-ALL cells is sensitive to INSR/IGF-1R inhibition without presenting any activating mutations in these receptor kinase-coding genes39,40. The gene discussed is IGF1R; the disease is acute lymphoblastic leukemia.